The Facts: Biologics & Biosimilars

Clinical Spotlight: Brenzavvy and Other Newly Approved Therapies

Our Fall Clinical Forum highlights Brenzavvy (bexagliflozin), a lower-cost option for type 2 diabetes, and shares clinical recommendations for newly approved therapies.

Read More

Clinical Insights for New-to-Market Drugs

We’re committed to offering timely, clinically relevant information about newly approved medications. These updates are designed to assist with the development of criteria for clinical review, prior authorization, or utilization management strategies.

Read More